SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Reckitt Benckiser Group plc (RBGPF) trades at a trailing P/E of 14.1, forward P/E of 20.4. Trailing earnings yield is 7.08%, forward earnings yield 4.91%. PEG 0.10 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (85/100, Pass) — P/E is below market average (14.1); PEG ≤ 1.0 — Peter Lynch undervalued (0.10); earnings yield beats bond yields (7.08%).
- PEG Ratio 0.10 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 7.08% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 69/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
85/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RBGPF
Valuation Multiples
P/E (TTM)14.1
Forward P/E20.4
PEG Ratio0.10
Forward PEG1.77
P/B Ratio0.00
P/S Ratio3.17
EV/EBITDA0.0
Per Share Data
EPS (TTM)$4.87
Forward EPS (Est.)$3.38
Book Value / Share$0.00
Revenue / Share$21.72
FCF / Share$0.00
Yields & Fair Value
Earnings Yield7.08%
Forward Earnings Yield4.91%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.57 |
$9.89B |
$1.83B |
18.5% |
| 2017 |
$8.68 |
$11.51B |
$6.17B |
53.6% |
| 2018 |
$3.05 |
$12.6B |
$2.16B |
17.1% |
| 2019 |
$-3.91 |
$12.85B |
$-2.77B |
-21.6% |
| 2020 |
$1.66 |
$13.99B |
$1.19B |
8.5% |
| 2021 |
$-0.07 |
$13.23B |
$-52M |
-0.4% |
| 2022 |
$3.26 |
$14.45B |
$2.33B |
16.1% |
| 2023 |
$2.29 |
$14.61B |
$1.64B |
11.2% |
| 2024 |
$2.01 |
$14.17B |
$1.43B |
10.1% |
| 2025 |
$4.87 |
$14.2B |
$3.18B |
22.4% |
